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Available online 29 October 2011Rationale: Analyses of circulating cell membrane-derivedmicrovesicles (MV) have come under
scrutiny as potential diagnostic and prognostic biomarkers of disease. However, methods to
isolate, label and quantify MV have been neither systematized nor validated.
Objective: To determine how pre-analytical, analytical and post-analytical factors affect plasma
MV counts, markers for cell of origin and expression of procoagulant surface phosphatidylserine.
Methods and results: Peripheral venous blood samples were collected from healthy volunteers
and patients with cardiovascular disease and/or diabetes. Effects of blood sample collection, an-
ticoagulant and sample processing to platelet free plasma (PFP), and MV isolation, staining and
storage (freeze–thaw) and cytometer design were evaluated with replicate samples from these
populations. The key finding is that use of citrate or EDTA anticoagulants decreases or eliminates
microvesicles from plasma by inducing adhesion of themicrovesicles to platelets or other formed
elements. Protease inhibitor anticoagulants, including heparin, preserveMV counts. A centrifuga-
tion protocol was developed in which recovery of isolated MVwas high with resolution down to
the equivalent light scatter of 0.2 μm latex beads. Each procedure was systematically evaluated
for its impact on the MV counts and characteristics.
Conclusion: This study provides a systematic methodology for MV isolation, identification and
quantification, essential for development ofMV as diagnostic and prognostic biomarkers of disease.
© 2011 Elsevier B.V. Open access under CC BY-NC-ND license. Keywords:
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Pre-analytical and analytical variables1. Introduction
During cell activation, apoptosis or intercellular interac-
tions, sealed unilamellar plasma membrane vesicles areplasma; PFP, platelet
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Y-NC-ND license. shed into circulation (Lynch and Ludlam, 2007; Piccin
et al., 2007; Cocucci et al., 2009). The terms ‘microvesicles’
and ‘microparticles’ have been interchanged, but ‘microve-
sicles’ (MV) distinguish membrane-derived vesicles from
othermicroparticles including lipoproteins, protein aggregates,
non-membranous debris, and exosomes. The concentration
and composition of MV in the circulation depend upon their
cells of origin and the stimuli that trigger their production.
Thus, populations of circulatingMVbear pathophysiological in-
formation, and so have potential for use as sensitive and specif-
ic biomarkers for presymptomatic disease. MV have been
investigated for prognosis in coronary artery syndrome, aneu-
rysm, thrombosis, pulmonary embolism, thrombotic thrombo-
cytopenic purpura, paroxysmal nocturnal hemoglobinuria,
heparin induced thrombocytopenia, sickle cell disease, sepsis,
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proliferative disorder and some types of cancer (Zwaal and
Schroit, 1997; Berckmans et al., 2001; VanWijk et al., 2003;
Morel et al., 2006; Zwicker et al., 2007; Toth et al., 2008a,b).
We reported that concentrations of platelet and endothelium-
derived MV were elevated in plasma samples from recently-
menopausal women who were at low risk for cardiovascular
disease by Framingham scores but who had unexpected coro-
nary calcification (Jayachandran et al., 2008).
Methods for isolation, identification, characterization and,
especially, enumeration of circulatingMVhave not been validat-
ed completely. Several reviews of the topic have emphasized the
need for validation of pre-analytical procedures, including anti-
coagulants and isolationmethods, and for analytical procedures,
including reagent compositions, instrument settings and calibra-
tion (Kim et al., 2002; Horstman et al., 2004; Jy et al., 2004;
Michelsen et al., 2006; Enjeti et al., 2007; Lynch and Ludlam,
2007; Shet, 2008; Dey-Hazra et al., 2010; van Ierssel et al.,
2010; Ayers et al., 2011; Yuana et al., 2011). The present study
was undertaken to define pre-analytical, analytical and post-
analytical factors in MV analysis and to refine, standardize and
validate methods for isolation, identification, quantification and
characterization of MV in peripheral blood samples.
2. Materials and methods
2.1. Antibodies and other reagents
Annexin-V and mouse anti-human CD42a, CD61 and 62E
conjugated with fluorescein isothiocynate (FITC) or R-
phycoerythrin (PE) and TruCOUNT™ (4.2 μm) beads were
purchased from BD Biosciences, San Jose, CA. Fluorescent
latex beads (1 μm and 2 μm) were purchased from Sigma-
Aldrich, Saint Louis, Missouri. Fluoresbrite® Microparticles
(0.2 μm, 0.5 μm, 1 μm and 2 μm) were purchased from Poly-
sciences, Inc., Warrington, PA. Soybean trypsin inhibitor was
purchased from Sigma, St. Louis, MO, hirudin from CIBA
GEIGY Ltd, Basle, Switzerland, and paraformaldehyde (16%
solution, EM grade) from Electron Microscopy Sciences,
Hatfield, PA. Blood collection tubes were purchased from
Becton, Dickson and Company, Franklin Lakes, NJ.
2.2. Samples
All studies were approved by the Mayo Clinic Institutional
Review Board. Blood samples were collected from 120 male
and female participants (19–85 years of age) who were either
apparently healthy or diagnosedwith type II diabetes, coronary
artery disease (CAD)with andwithout diabetes, or prior stroke
or venous thromboembolism. These participants were selected
to provide a wide range of MV counts and properties. Samples
were collected through a 19 gauge butterfly needle by slow-fill
syringe, and after discard of the initial 2–3 mL, dispensed into
tubes containing either 15% ethylenediaminetetraacetic acid
(EDTA), 3.2% NaCitrate (citrate; 0.11 M), Acid Citrate Dextrose
(ACD, Solution B), sodium heparin (68 USP Units) or a mix of
1 μMhirudin plus a factor Xa inhibitor (10 μMSoybean Trypsin
Inhibitor or 10 μMTick Anticoagulant Peptide; H&S). The use of
the trypsin inhibitor, which on its own is a weak anticoagulant,
has supplanted that of the tick anticoagulant, no longer avail-
able. We have not established that addition of either Xainhibitor is essential, but we have determined (unpublished
observation) that factor X can become activated in plasma
anticoagulated only with hirudin. Platelet P-selectin, PAC-1
binding and phosphatidylserine were determined as described
(Jayachandran et al., 2008).
2.3. Isolation of blood MV
The method is published in part (Jayachandran et al., 2008).
Essentially platelet free plasma (PFP) was prepared from anti-
coagulated blood by double centrifugation at 3000×g for
15 min. The PFP (0.5–1 mL) was centrifuged at 20,000×g for
30 min in an angle-head rotor. The supernatant plasma was
subjected to a second centrifugation at 60,000×g for 30 min;
this supernatant was then stored at −80 °C for subsequent
analysis. The MV pellet obtained from each centrifugation was
reconstituted by vortex mixing (1–2 min) with 0.5–1 mL of
Hanks'/HEPES (130 mM NaCl, 5.4 mM KCl 1.3 mM CaCl2,
0.8 mM MgSO4, 0.44 mM Na2HPO4, 20 mM HEPES, pH 7.4). All
solutions were filtered twice through 0.2 μmmembrane (Milli-
pore) filters. Each washed suspension containing MV was then
centrifuged again at 20,000×g or 60,000×g for 30 min and the
resulting pellet reconstituted with 0.5 or 1 mL of fresh buffer.
2.4. Flow cytometry
Unless otherwise indicated, all analyses used a FACSCanto II
cytometer (BD Biosciences, San Jose, CA). A sample of isolated
MV (50 μL) was incubated with 4 μL of annexin-V-FITC and
PE-conjugated mouse anti-human CD42a or CD61) for
25–30 min. These times and concentrations had been optimized
by titration of each reagent. Where indicated, stained MV were
fixed by dilution with 400 μL of 1% paraformaldehyde for
15 min. For calculation of counts, TruCOUNT™ beads (50 μL)
were added immediately prior to analysis by flow cytometry.
Gain settings were adjusted to place the TruCOUNT™ beads in
the upper log for scatter. Unfiltered Isoton® II diluent from
Beckman Coulter, Fullerton, CA, was used in cytometers. Com-
pensation for channel spill was calculated using the auto-
compensation feature from recorded values of separate and
combined unstained and single-stained MV. Auto-calculated
compensation parameters were verifiedmonthly. All antibodies
were filtered twice through 0.2 μmmembrane filters. Unfiltered
buffers and antibodies contain interfering numbers of chemical
microparticles (data not shown). MV are defined in this study
as events b1 μm in diameter and positive for annexin-V and
cell-specific markers. The thresholds were set with isotype
control fluorescent antibodies. MV prepared and stained in
phosphate buffered saline or HEPES buffered saline (HBS; pH
7.4) without calcium served as negative controls for annexin-
V. The absolute count of MV either in the absence or presence
of single or dual staining was calculated with the relation:
MV ¼ GMV
GTC
TC
V
where GMV is the number of events in the MV gate, GTC is the
number of events in the TruCOUNT™ bead gate, and TC is the
number of TruCOUNT™ beads added to the sample of volume
V (Shet et al., 2003; Jayachandran et al., 2008). Except for com-
parison of instruments, the FACSCanto™ flow cytometer was
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data are shown as mean±SD.
2.5. Direct analysis of plasma
PFP (5 μL) was diluted 1/20 with Hanks'/HEPES (pH7.4), and
then 4 μL of fluorochrome-conjugated annexin-V and cell-
specific antibodies were added. These mixtures were briefly
vortexed and incubated in the dark for 25–30 min at room tem-
perature. The mixture was diluted with 800 μL of Hanks'/HEPES
or buffered saline solution (HBS; 20 mM HEPES, 150 mM NaCl,
2.5 mM calcium) and 100 μL of TruCOUNT™ beads.
3. Results
3.1. Data acquisition
Side scatter events from size calibration beads of 0.2 μm,
0.5 μm, 1 μm and 2 μm were resolved from instrument noise
with the 18-bit FACSCanto (105-channel) flow cytometer
(Fig. 1). Inspection of the scatter plot (Fig. 1B) indicates that
0.2 μm is the lower limit for beads, which have a higherFig. 1. Representative dot plots from the FACSCanto flowcytometer. R1 is the gate for all e
beads, including TruCOUNT™ (TC). A. Reagent blank: buffer plus fluorochrome-conjugat
side scatter of isolated microvesicles stained with Fluorescein (FL)-annexin-V and Phyco
quadrant lines dividing positive from negative events are drawn to include the maximalindex of refraction, and therefore lower size threshold, than
membrane vesicles (Koch et al., 1966; Foladori et al., 2008;
Lacroix et al., 2010; Yuana et al., 2011). More than 90% of
MV isolated from plasma showed scatter intensities lower
than that of 1 μm beads (Fig. 1C). Fluorescence events from
anti-CD42a and annexin V from within the MV scatter gate
accounted for more than 99% of events (Fig. 1C). For the sam-
ple shown in Fig. 1D, all but a small fraction (Q4) of counts
were positive for both ligands, a finding typical for platelet
MV (Jayachandran et al., 2008). MV counts were calculated
from the nominal number of beads added per volume of
sample, with a minimum of 1000 TruCOUNT™ bead events
(typically 2500) per analysis. The coefficient of variation of
ten aliquots of 0.5, 1 and 2 μm beads was 7.2%, 2.6% and
2.4%, and MV counts calculated with the TruCOUNT™ inter-
nal standard were not significantly affected by flow rate.
3.2. Preanalytical issues
3.2.1. Anticoagulants
The choice of anticoagulant had a substantial impact on
both platelet and endothelial MV counts (Fig. 2). Both plateletvents,MV is themicrovesicle gate, and the remainders are gates for the calibration
ed annexin V and anti-CD 42a; B. Reagents plus calibration beads; C. Forward and
erythrin (PE)-anti-CD42a (GPIX) and the TruCOUNT™ internal calibrator; D. The
number of positive events above 95% the events seen with the isotype controls.
Fig. 2. Impact of anticoagulants. Upper panel, platelet (CD42a) MV obtained
in blood from the same individuals collected in different anticoagulants.
Data are shown as mean±SD; n=12. Lower panel, endothelial (CD62E)
MV. Lines connect paired data from 63 individuals. Asterisks denote
Pb0.05 relative to H&S.
Fig. 3. Anticoagulants in cell-free plasma. Anticoagulants as indicated were
added to plasma obtained by immediate brief centrifugation of blood col-
lected without anticoagulant. Data are shown as mean±SD; n=12. The
last bar is the MV count from whole blood (WB) collected in H&S anticoag-
ulant from the same individuals.
Fig. 4. Point of loss of MV with chelating anticoagulants. Top: Whole blood
(WB) was collected in H&S (left) or heparin (Hep; right), centrifuged to obtain
PRP and then the indicated anticoagulants were added. Bottom: Whole blood
was collected with citrate (left) or EDTA (right) anticoagulant, centrifuged to
obtain PRP, and then the indicated anticoagulants were added. Then, PFP was
prepared from each sample and analyzed for platelet MV counts. Data are
shown as mean±SD; n=10. Asterisks denote Pb0.05 against WB.
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lected in calcium chelating anticoagulants versus protease in-
hibitors. When counts were above the 90th percentile,
endothelial (CD62-E positive) MV were effectively eliminated
(Pb0.003) in preparations from blood collected in sodium cit-
rate compared to H&S. When counts were in the range typical
of healthy donors, the counts for platelet MV in citrate plasma
averaged 30–40% of the counts in hirudin and soy bean trypsin
inhibitor (H&S; endothelial MV were not detected in plasmas
from the normal donor pool). However, the ratio of annexin-
V positive to negative MV was not sensitive to anticoagulant
(r2=0.08). MV recovery was the same from blood collected
in Vacutainer or non-Vacutainer tubes containing the same
concentration of calcium chelating and protease inhibitor anti-
coagulants (not shown).
Does calcium chelation suppress MV recovery or do prote-
ase inhibitors stimulate shedding? The results with endothelial
MV suggest suppression. We had observed that there was a
window of as long as 10 min between phlebotomy and mixing
of the blood with anticoagulant during which the MV count
was stable. Accordingly, blood (1 mL aliquots) without antico-
agulant was centrifuged immediately for 2 min at 8000×g or
for 10 min at 3000×g, and then anticoagulants were added to
these platelet poor plasmas (PPP). Addition of any anticoagu-
lant to PPP thus prepared from non-anticoagulated blood
yielded the same number of annexin-V positive MV as blood
collected in H&S anticoagulant (Fig. 3).The basis for the loss of MV with removal of calcium was
addressed by shifting the point of addition of anticoagulants.
Adding either calcium chelating or protease inhibitor antico-
agulants to isolated MV did not alter MV counts (data not
shown). When calcium chelators were added to the platelet
rich plasma (PRP) prepared from the first 800×g spin of
blood collected in H&S or heparin (Fig. 4, top), platelet MV
counts decreased to an extent similar to that seen in whole
blood with citrate or EDTA anticoagulants (Fig. 4, bottom).
In contrast, addition of H&S or heparin to PRP prepared
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not further affect numbers of MV (Fig. 4, bottom).
3.2.2. Time and temperature
Whole blood collected in either citrate or H&S was distrib-
uted into 1.5 mL tubes and maintained at either room tem-
perature (ca. 22 °C) or 33 °C for up to 3 h, during which MV
counts were obtained at intervals. For whole blood collected
in citrate, counts of annexin-V positive and platelet MV de-
creased within 15 min and were significantly lower after
one hour at either temperature (data not shown). In contrast,
counts of annexin-V and platelet MV did not change signifi-
cantly within the first hour at either temperature in blood
collected in H&S but increased significantly thereafter
(Fig. 5). The increase in counts of stained MV was greater at
room temperature than at 33 °C. However, the percentage
of platelets expressing surface P-selectin, activated glycopro-
tein αIIbβ3, phosphatidylserine remained b5% in all samples.
Counts of endothelial MV did not change during the three
hours at either temperature.
3.2.3. Recovery after centrifugation
Centrifugation of PFP at 20,000×g recovered on average 80%
of the MV measured by direct staining of PFP (r2=0.8). More
than 90% of platelet MV were recovered after a wash with
Hanks'/HEPES of MV pelleted by the 20,000×g centrifugation
(n=66). Less than 10% additional platelet MV were isolated
when plasma supernatants from the 20,000×g centrifugationFig. 5. Stability of MV counts in blood in vitro. Blood was collected in H&S
andmaintained at either (A) 33 °C or (B) room temperature. At the indicated
times samples (n=10) were centrifuged and analyzed for platelet MV
counts. Endothelial MV (C) were analyzed in samples from blood at both
temperatures. Each line represents MV recovered from a single individual.
Asterisks denote Pb0.05 relative to zero.were centrifuged a second time at 60,000×g for 30 min. Typical
of isolation procedures, the recovery increased from a low of
50% at the lowest MV counts up to 80% at the highest counts.
Scatter signals from MV isolated by ultracentrifugation
(Fig. 1B)were better resolved than those obtained from samples
analyzed by direct staining of PFP or unwashed MV (Fig. 6),
which showed substantial populations of microparticles nega-
tive for all stains (Fig. 6, red dots).3.2.4. Storage and freeze–thaw
Counts of MV were the same when isolated from either
PFP or PPP stored at either -40 °C or −80 °C for more than
a year. Up to three freeze thaw cycles of PFP had no effect
on MV counts, irrespective of initial counts (Fig. 7). Once iso-
lated, counts of isolated MV were stable during storage at
room temperature for 3–4 days. However, a single freeze
and thaw of isolated MV at either −20 °C, −40 °C or
−80 °C lowered the count by 10–15%.Fig. 6. Direct staining of MV in dilute plasma. A. Dot plot of MV contaminated
with plasma, color-coded according to staining for CD42a and annexin-V
(blue); B. Quadrant plot of the MV gate in A.
Fig. 7. Stability of MV counts in plasma after freezing. Plasma frozen by plac-
ing the samples (1 mL) in a−70 °C freezer were then subjected to repeated
freeze-thaw cycles (top panel) or left undisturbed for a minimum of one
year and then (lower panel) thawed and assayed (B) for comparison to
the values obtained for the original pre-frozen sample (A).
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3.3.1. Count calibration
The assumption that the nominal TruCOUNT™ bead count
is valid was verified by a cross-check with erythrocyte counts
and a validated Coulter counter (Fig. 8). As the erythrocyte
count in each sample increased above the order of the
(constant) TruCOUNT™ bead concentration, the red blood
cells (RBC) event rate increased in linear proportion to the
RBC count while the TruCOUNT™ bead event rate declined.
Because the TruCOUNT™ calibration is in the denominatorFig. 8. Validation of TruCOUNT™ bead calibration. A suspension of washed
fixed erythrocytes (1.8×106/μL) were counted with a calibrated particle
counter (Beckman Coulter ACT diff 2) and then diluted as indicated into
0.5 mL of Hanks'/HEPES solution containing 5000 TruCOUNT™ beads (10
μL). Erythrocyte counts (solid circles) were calculated from FACSCanto
data by reference to the internal standard TruCOUNT™ beads as described
in Materials and methods. The dashed arrow is the initial erythrocyte
count determined with the Coulter counter./(Materials and methods), the calculated erythrocyte count
showed a systematic increase (solid line/symbols) above
that obtained with the Coulter counter (dashed line). Extrap-
olation of the linear increase to the erythrocyte count of zero
intersected the count axis within 5% of the Coulter counter
value, and showed a systematic error of +10% when the
count rate was 1000 times that of the TruCOUNT™ rate. Be-
cause analysis with other bead calibrators has been published
(Robert et al., 2008), we analyzed mixtures of BD TruCOUNT™
beads (4.2 μm) with Beckman-Coulter Flow-Check (10 μm)
beads for counts obtained by scatter and by fluorescence. In
all cases, scatter and fluorescence data were congruent. Two
lots of the Flow-Check beads yielded counts of 50% of nominal
or less when the TruCOUNT™ count rates were of the order of
20–30/s. At lower bead dilutions (higher count rates), the BD
beads yielded proportional counts whereas the Flow-Check
beads were disproportionately undercounted. We did not in-
vestigate this disparity further.
4. Discussion
Distinct populations of circulating MV have been observed
in a variety of disease conditions, often related to inflammatory
processes (Zwaal and Schroit, 1997; Berckmans et al., 2001;
VanWijk et al., 2003; Morel et al., 2006; Jayachandran et al.,
2008, 2009). However, the potential for MV as biomarkers
has been limited by inadequate validation and standardization
of sample preparation, reagents and instrument parameters (Jy
et al., 2004; Lynch and Ludlam, 2007). The importance of sam-
ple acquisition and processing to obtain platelet poor plasma
has been addressed (Jy et al., 2004; Shah et al., 2008; Shet,
2008; Dignat-George et al., 2009) but without a systematic
analysis of individual parameters. The present investigation
was undertaken to fill this gap in the literature by evaluating
factors that affect MV analysis in terms of venous sample col-
lection, anticoagulants, isolation techniques, staining methods
and storage and cytometer settings. An important feature of
the present approach was to assess all of these parameters on
blood from diverse groups of healthy and diseased individuals
so that findings may be generalized.
4.1. Anticoagulant
A paramount finding of this study is the impact of anticoagu-
lants on MV recovery. Counts of platelet and endothelial MV
were substantially lower in blood collected in citrate or EDTA
than in blood collected in protease inhibitors, either H&S or hep-
arin. This effect of anticoagulants was interpreted by Shah et al.
(2008) as arising from microvesiculation in vitro with protease
inhibitor anticoagulants. However, results of the present study
provide an alternative conclusion, first because endothelial MV,
which cannot be generated in blood in vitro, were effectively re-
moved with chelation of whole blood. Therefore, the difference
inMV counts obtained in calcium chelating anticoagulants com-
pared to protease inhibiting anticoagulants reflects loss with
chelation rather than gain with protease inhibitors. This conclu-
sion is verified by the finding that adding any anticoagulant to
platelet-free plasma prepared without an anticoagulant had no
effect onMV counts, whichwere congruent with those obtained
from whole blood anticoagulated by protease inhibition.
Chelation-induced association of the MV with platelets is
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lated with PRP prepared from blood collected in protease inhi-
biting anticoagulants. Because the degree of loss with chelation
is unpredictable, with relative proportions of annexin-V positive
and negative platelet MV not falling in predictable register, all
prior work on MV from blood anticoagulated by citrate, ACD
and EDTA (Jy et al., 2004) may need reevaluation. That said,
our MV counts from citrated plasma lie within the lower group
of the wide range among published studies (Yuana et al.,
2011). Platelet MV counts remained constant when either H&S
or heparin anticoagulated blood was maintained for up to
60 min at 33 °C, and for 30 min at room temperature, but there-
after increased. The temperature effect is commensurate with
the sensitivity of platelet shape change as blood cools (Tablin
et al., 2000). Counts of endothelial MV did not change over
time at either temperature, to indicate that the increase reflected
release of MV from the platelets.4.2. Bead calibration
There is growing and compelling evidence that flow cyto-
metry resolves only the largest membrane vesicles, which
comprise a near-negligible portion of the total (Koch et al.,
1966; Foladori et al., 2008; Zwicker et al., 2009; Lacroix et al.,
2010; Yuana et al., 2010; Chandler et al., 2011; Yuana et al.,
2011). Visualization of plasma or thrombin-stimulated platelet
microvesicles by atomic force microscopy (Yuana et al., 2010)
indicates a median diameter of 60 nm. Counts obtained from
the AFM images averaged 1000 times those obtained by flow
cytometry using an isolation and staining protocol similar to
ours, and which yielded similar counts. Direct measurement
of placental and plasma MV by refractive index-independent
particle tracking with simultaneous extraction of translational
diffusion coefficients likewise detected the order of 107 cellular
MV/μL of plasma, more than four orders of magnitude times
that detected by flow cytometry (Dragovic et al., 2011). Using
synthetic microvesicles of defined size, Chandler et al. (2011)
verified that the most sensitive flow cytometers cannot detect
single microvesicles smaller than about 400 nm. And finally
measurements of microvesicle procoagulant activity directly
in plasma (Mallat et al., 2000; Owen et al., 2011) yield activities
at least 3–4 orders of magnitude higher than can be accounted
for by annexin-V positivemicrovesicle counts obtained by flow
cytometry. However, microvesicle analysis by flow cytometry
has yielded correlations to inflammatory and vascular patho-
physiology, and continues to dominate the MV literature, so
continuing standardization and validation of reagents and sam-
ple preparation remains essential in the face of the high vari-
ability among laboratories (Yuana et al., 2011).
The basis for the disparity between BD TruCOUNT™ and
Beckman-Coulter calibrators is not clear. Undercounting of a cal-
ibrator might account for exceptionally high MV counts (Shah
et al., 2008). We validated the TruCOUNT™ calibration against
a washed erythrocyte suspension counted with a Coulter coun-
ter. The TruCOUNT™ beads are provided in single use tubes,
whereas the Flow-Check are provided in a single bottle for re-
petitive sampling and thus might be prone to sampling error
secondary to incomplete mixing. However, we found a fresh
bottle of Flow-Check beads to yield under-counts comparable
to those of a nearly exhausted bottle. We did not evaluate thedisparity with a cytometer other than the FACSCanto, but no
theoretical basis for a cytometer-specific disparity is obvious.
4.3. Isolation and staining
Isolation of MV with 20,000×g centrifugation of platelet
free plasma resulted in the loss of as much as 20% of the
counts obtained with direct staining, but the fidelity of the
signal was higher. This enhanced resolution may reflect the
removal of microparticulate lipids and proteins aggregates.
Although it adds a significant pre-analytical step, isolation
rather than direct staining is essential for analyzing batches
of samples, as plasma clogs the flow tubes and carries over.
At best, a 1/200 dilution of the plasma is required for optimal
staining and analysis and so decreases the sensitivity for low
abundant MV signals.
Unfixed samples yielded variably fewer MV, which could
arise from MV aggregation or adsorption to the sample tubes
and instrument plumbing. We have not evaluated other possi-
ble inhibitors of MV loss, but there may be alternatives to para-
formaldehyde, which provide acceptable inter-assay variability
of b10%.
4.4. Storage
Up to three freeze–thaw cycles of PFP did not affect MV
recovery. Storage of PPP (prepared by single centrifugation
of PFP at 3000×g for 15 min) for more than a year minimally
and randomly affected MV recovery.
5. Conclusions
Among pre-analytical procedures that affect yield and re-
producibility of microvesicle analysis, choice of anticoagulant
and centrifugation protocols for preparing platelet free plas-
ma and isolated microvesicles have major influences. Other
significant influences arise from time and temperature be-
tween phlebotomy and initial centrifugation, freezing of the
isolated microvesicles and internal calibration. Freezing of
plasma, essential for large scale studies, has no effect on the
microvesicle counts.
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